1. Bloom DE, Cadarette D. Infectious disease threats in the twenty-first century: strengthening the global response. Front Immunol. 2019; 10:549.
Article
3. Kim JH. Recent trends in anti-vaccine movement and future directions. Korean J Pediatr Infect Dis. 2007; 14:37–42.
Article
4. Kovaiou RD, Herndler-Brandstetter D, Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med. 2007; 9:1–17.
Article
5. Oh MD, Lee JK. Milestones in history of adult vaccination in Korea. Clin Exp Vaccine Res. 2012; 1:9–17.
Article
6. Korean Society of Infectious Diseases. Guideline for adult immunization 2019 [Internet]. Seoul: Korean Society of Infectious Disease;2019. cited 2019 Dec 24. Available from:
http://www.ksid.or.kr/data/sub07.html.
8. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008; 197 Suppl 2:S207–S215.
Article
9. Oxman MN, Levin MJ. Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008; 197 Suppl 2:S228–S236.
Article
11. Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018; 67:103–108.
Article
12. Yoo SM. Cost-effectiveness analysis of vaccination against herpes zoster in older adults aged over 60 years in Korea [dissertation]. Seoul: Seoul National University;2014.
13. Korea Centers for Disease Control and Prevention. Web statistics system for infectious disease [Internet]. Cheongju: Korea Centers for Disease Control and Prevention;2019. cited 2019 Dec 24. Available from:
https://is.cdc.go.kr/.
14. Lee HY, Park YJ, Park O. Incidence and epidemiology of Japanese encephalitis in Korea. Public Health Wkly Rep KCDC. 2015; 8:433–436.
15. Chokephaibulkit K, Houillon G, Feroldi E, Bouckenooghe A. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV) in children. Expert Rev Vaccines. 2016; 15:153–166.
Article
16. Jeong CW, Park YJ. Status of pertussis incidences in Korea, 2012. Public Health Wkly Rep. 2013; 6:569–573.
18. Status of pertussis incidences in Korea, 2018. Public Health Wkly Rep. 2018; 29:1–2.
19. Kwon HJ, Yum SK, Choi UY, Lee SY, Kim JH, Kang JH. Infant pertussis and household transmission in Korea. J Korean Med Sci. 2012; 27:1547–1551.
Article
21. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014; 63:822–825.
22. Song JY, Cheong HJ. Pneumococcal vaccine. J Korean Med Assoc. 2014; 57:780–788.
Article
23. Choi WS, Choi JH, Kwon KT, Seo K, Kim MA, Lee SO, Hong YJ, Lee JS, Song JY, Bang JH, Choi HJ, Choi YH, Lee DG, Cheong HJ. the Committee of Adult Immunization, the Korean Society of Infectious Diseases. Revised Adult Immunization Guideline recommended by the Korean Society of Infectious Diseases, 2014. Infect Chemother. 2015; 47:68–79.
Article